Search Results - "BARDHAN, K. D."

Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention by Pattni, S. S., Brydon, W. G., Dew, T., Johnston, I. M., Nolan, J. D., Srinivas, M., Basumani, P., Bardhan, K. D., Walters, J. R. F.

“…Summary Background Bile acid diarrhoea is a common, under‐diagnosed cause of chronic watery diarrhoea, responding to specific treatment with bile acid…”
Get full text

Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982–2002 by KANG, J. Y., ELDERS, A., MAJEED, A., MAXWELL, J. D., BARDHAN, K. D.

“…Summary Background While overall hospital admission rates for peptic ulcer declined in England in the 1990 s, they increased among the elderly, especially for…”
Get full text

Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire? by STANGHELLINI, V, ARMSTRONG, . D, MÖNNIKES, H, BARDHAN, K. D

“…Gastro-oesophageal reflux disease (GERD) is highly prevalent in Western countries. Because the majority of patients do not present with endoscopic…”
Get full text

Breathomics--exhaled volatile organic compound analysis to detect hepatic encephalopathy: a pilot study by Arasaradnam, R P, McFarlane, M, Ling, K, Wurie, S, O'Connell, N, Nwokolo, C U, Bardhan, K D, Skinner, J, Savage, R S, Covington, J A

“…The current diagnostic challenge with diagnosing hepatic encephalopathy (HE) is identifying those with minimal HE as opposed to the more clinically apparent…”
Get more information

Tegaserod, a 5‐HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation by Müller‐Lissner, S. A., Fumagalli, I., Bardhan, K. D., Pace, F., Pecher, E., Nault, B., Rüegg, P.

“…Aim: To investigate the efficacy and safety of tegaserod, a novel 5‐HT4 receptor partial agonist, in a randomized, double‐blind, placebo‐controlled, 12‐week…”
Get full text

A double‐blind, randomized, placebo‐controlled dose‐ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome by Bardhan, Bodemar, Geldof, Schütz, Heath, Mills, Jacques

“…Background: Irritable bowel syndrome is a common gastrointestinal disorder characterized by abdominal pain and discomfort and altered bowel habit. Antagonism…”
Get full text

A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving ‘complete remission’ in gastro‐oesophageal reflux disease by BARDHAN, K. D., ACHIM, A., RIDDERMANN, T., PFAFFENBERGER, B.

“…Summary Background and Aim  The outcome of gastro‐oesophageal reflux disease treatment is traditionally assessed by measuring endoscopically confirmed healing…”
Get full text

International validation of ReQuest in patients with endoscopy‐negative gastro‐oesophageal reflux disease by Bardhan, K. D., Stanghellini, V., Armstrong, D., Berghöfer, P., Gatz, G., Mönnikes, H.

“…Summary Background : Reflux Questionnaire (ReQuest), a newly developed gastro‐oesophageal reflux disease‐sensitive scale, can be used to reliably evaluate the…”
Get full text

The scars of time: the disappearance of peptic ulcer-related pyloric stenosis through the 20th century by Hall, R, Royston, C, Bardhan, K D

“…The changing pattern of haemorrhage and perforation from peptic ulcer disease is well documented but little is known about pyloric stenosis, the third…”
Get full text

Intestinal secretory and absorptive function in Trichinella spiralis mouse model of postinfective gut dysfunction: role of bile acids by Kalia, N, Hardcastle, J, Keating, C, Grasa, L, Pelegrin, P, Bardhan, K D, Grundy, D

“…Observations showing that bile acid malabsorption is frequent in irritable bowel syndrome (IBS) suggest that alterations in bile acid-induced secretion and…”
Get more information

One week triple therapy for Helicobacter pylori: a multicentre comparative study by Misiewicz, J J, Harris, A W, Bardhan, K D, Levi, S, O’Morain, C, Cooper, B T, Kerr, G D, Dixon, M F, Langworthy, H, Piper, D

“…Background—Eradication ofHelicobacter pylori cures and prevents the relapse of duodenal ulceration and also results in histological resolution of chronic…”
Get full text

Primary gastroduodenal prophylaxis with omeprazole for non‐steroidal anti‐inflammatory drug users by CULLEN, D, BARDHAN, K. D, EISNER, M, KOGUT, D. G, PEACOCK, R. A, THOMSON, J. M, HAWKEY, C. J

“…Aim: To investigate the efficacy of omeprazole 20 mg o.m. as primary prophylaxis against non‐steroidal anti‐inflammatory drug (NSAID)‐associated ulcer disease…”
Get full text

Development and application of a new electronic nose instrument for the detection of colorectal cancer by Westenbrink, E, Arasaradnam, R P, O'Connell, N, Bailey, C, Nwokolo, C, Bardhan, K D, Covington, J A

“…Colorectal cancer is a leading cause of cancer death in the USA and Europe with symptoms that mimick other far more common lower gastrointestinal (GI)…”
Get full text

The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies by Lind, Tore, Mégraud ‡, Francis, Unge §, Peter, Bayerdörffer ∥, Ekkehard, O'Morain ¶, Colm, Spiller #, Robin, van Zanten, Sander Veldhuyzen, Bardhan ‡‡, Karna Dev, Hellblom §§, Magnus, Wrangstadh ∥∥, Michael, Zeijlon ∥∥, Lars, Cederberg ∥∥, Christer

“…Background & Aims: The role of omeprazole in triple therapy and the impact of Helicobacter pylori resistance on treatment outcome are not established. This…”
Get full text

A randomized, double‐blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro‐oesophageal reflux disease over 5 years by Thjodleifsson, B., Rindi, G., Fiocca, R., Humphries, T. J., Morocutti, A., Miller, N., Bardhan, K. D.

“…Summary Background : Gastro‐oesophageal reflux disease has a chronic course, and often requires long‐term treatment. Proton pump inhibitors are the treatment…”
Get full text

Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine by Bardhan, K D, Müller-Lissner, S, Bigard, M A, Porro, G Bianchi, Ponce, J, Hosie, J, Scott, Mairi, Weir, D G, Gillon, K R W, Peacock, R A, Fulton, Claire

“…Abstract Objective: To assess intermittent treatment over 12 months in patients with symptomatic gastro-oesophageal reflux disease. Design: Randomised,…”
Get full text

The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease by Bardhan, K D

“…Efficacy (healing, symptom relief) and cost-effectiveness are the principal reasons for the rapidly increasing use of proton pump inhibitors (PPIs) for the…”
Get more information

Emergency admissions for upper gastrointestinal disease and their relation to NSAID use by BLOWER, A. L., BROOKS, A., FENN, G. C., HILL, A., PEARCE, M. Y., MORANT, S., BARDHAN, K. D.

“…Background: There are considerable variations in estimates of the number of emergency upper gastrointestinal admissions per annum which are attributable to…”
Get full text

Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis by Bardhan, K. D., Van Rensburg, C.

“…Background: Several clinical trials have shown that pantoprazole (40 mg) and omeprazole (40 or 20 mg) have similar efficacy and safety in the treatment of…”
Get full text

Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia by Read, N W, Abitbol, J L, Bardhan, K D, Whorwell, P J, Fraitag, B

“…Background—Peripheral kappa receptor agonists may provide a new therapeutic approach for the treatment of functional dyspepsia. Aims—To evaluate, in a large…”
Get full text